BOSTON--(BUSINESS WIRE)--VITRAC Therapeutics, LLC (VITRAC) presented a poster on the Phase 1a/1b clinical trial of aurora kinase A (AURKA) inhibitor, VIC-1911, as monotherapy and in combination with KRAS G12C inhibitor, sotorasib. The study targets the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC). The findings were presented at the prestigious 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 4.
The clinical investigators involved in the study include S. B. Goldberg, MD, MPH, Principal Investigator (PI) and Study Chair at Yale Cancer Center, S. R. Punekar, MD, PI, NYU Langone-Laura and Isaac Perlmutter Cancer Center, V. Velcheti, MD, PI, New York University Perlmutter Cancer Center, J. W. Riess, MD, PI, University of California Davis Comprehensive Cancer Center, K. A. Scilla, MD, PI, University of Maryland Cancer Center, J. W. Carlisle, MD, PI, Emory University Winship Cancer Center, K. Politi, PhD, J.W. Lee, PhD, and B. Burtness, MD, Yale School of Medicine and Yale Cancer Center, T. Myers, MD, and L. Paradiso, DVM, Vitrac Therapeutics.
VIC-1911 is a highly selective, orally administered small molecule inhibitor of AURKA. Overexpression of the AURKA is found in multiple tumors, including NSCLC. New treatment approaches are urgently needed to mitigate and overcome resistance to KRAS G12C inhibitors.
Preclinical studies indicate that AURKA could play a role in resistance to KRAS G12C inhibitors. VIC-1911, both as monotherapy and in combination with a KRAS G12C inhibitors sotorasib and adagrasib, has shown effectiveness against NSCLC with intrinsic and acquired resistance to KRAS G12C inhibitors in preclinical models. These findings suggest the potential of VIC-1911, both as a monotherapy and in combination with sotorasib, for patients with KRASG12C-mutated NSCLC.
"We now have two approved KRAS G12C inhibitors, sotorasib and adagrasib, to treat patients with KRAS G12C-mutated NSCLC," stated Sarah Goldberg, MD, Study Chair. "Despite the satisfactory response rates in patients naïve to KRAS G12C inhibitor therapy, over 50% of patients exhibit primary resistance. Moreover, many patients who do respond soon develop acquired resistance and relapse. With this innovative approach combining AURKA and KRAS G12C inhibitors, we aim to enhance therapeutic outcomes for our patients with KRAS G12C-mutant NSCLC."
"VIC-1911 is a potent, selective AURKA inhibitor. The supporting preclinical studies strongly advocate for the combination of AURKA inhibition with VIC-1911 and KRAS G12C inhibitors in KRAS G12C-mutant NSCLC," said Thomas Myers, MD, Chief Medical Officer at VITRAC. "Through this multi-targeted approach, we hope to deliver more effective therapeutic outcomes for patients with KRAS G12C-mutant NSCLC."
About VITRAC Therapeutics, LLC:
VITRAC Therapeutics is a comprehensive oncology research and development company, excelling in the development, management, and optimization of global pharmaceutical drug development programs, from advanced discovery and translational research to clinical development, market authorization, and post-marketing life-cycle management.